Literature DB >> 21383308

Chlorthalidone versus hydrochlorothiazide as the preferred diuretic: is there a verdict yet?

John M Flack, Domenic A Sica, Shawna Nesbitt.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21383308     DOI： 10.1161/HYPERTENSIONAHA.110.164566

Source DB:  PubMed          Journal:  Hypertension        ISSN： 0194-911X            Impact factor:   10.190


× No keyword cloud information.
  7 in total

1.  Patterns of nonadherence to antihypertensive therapy in primary care.

Authors:  Larissa Grigoryan; Valory N Pavlik; David J Hyman
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-10-26       Impact factor: 3.738

Review 2.  Which diuretic is the preferred agent for treating essential hypertension: hydrochlorothiazide or chlorthalidone?

Authors:  F Wilford Germino
Journal:  Curr Cardiol Rep       Date:  2012-12       Impact factor: 2.931

3.  Fixed-dose combination pharmacologic therapy to improve hypertension control worldwide: Clinical perspective and policy implications.

Authors:  Donald J DiPette; Jamario Skeete; Emily Ridley; Norm R C Campbell; Patricio Lopez-Jaramillo; Sandeep P Kishore; Marc G Jaffe; Antonio Coca; Raymond R Townsend; Pedro Ordunez
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-11-27       Impact factor: 3.738

4.  Why are we still using hydrochlorothiazide?

Authors:  Clive Rosendorff
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-12-01       Impact factor: 3.738

5.  Race-Specific Comparisons of Antihypertensive and Metabolic Effects of Hydrochlorothiazide and Chlorthalidone.

Authors:  Lakshmi Manasa S Chekka; Arlene B Chapman; John G Gums; Rhonda M Cooper-DeHoff; Julie A Johnson
Journal:  Am J Med       Date:  2021-01-09       Impact factor: 5.928

Review 6.  Clinical utility of azilsartan-chlorthalidone fixed combination in the management of hypertension.

Authors:  Jerrica E Shuster; Barry E Bleske; Michael P Dorsch
Journal:  Vasc Health Risk Manag       Date:  2012-06-13

7.  A randomized titrate-to-target study comparing fixed-dose combinations of azilsartan medoxomil and chlorthalidone with olmesartan and hydrochlorothiazide in stage-2 systolic hypertension.

Authors:  William C Cushman; George L Bakris; William B White; Michael A Weber; Domenic Sica; Andrew Roberts; Eric Lloyd; Stuart Kupfer
Journal:  J Hypertens       Date:  2018-04       Impact factor: 4.844
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.